The information you provide to the chat will be recorded to improve your experience and to contact you. Please read our privacy notice to see how we are processing and protecting your data. Click to view our Cookie Notice.
We'd love your feedback—take a quick survey to help us improve.
How can we help you today?
Go from DNA to Phase I trials in just 8 months with integrated AI/ML-driven mAb manufacturing
Learn how advanced platform science, AI/ML-enabled cell line development, and integrated manufacturing capabilities can help speed up mAb programs while reducing risk
Biologics development doesn’t have to take decades. As monoclonal antibody (mAb) programs approach IND, inflexible processes, underperforming cell lines, and high-risk protocols have historically slowed program progress. But today, integrated AI/ML-driven manufacturing is offering sponsors a faster path forward—without compromising product quality.
How AI/ML-driven manufacturing is transforming biologics development
In a recent webinar presented in collaboration with BIO International, a Thermo Fisher Scientific biologics industry expert explains how our scientists are combining advanced platform science with US-based manufacturing to transform traditional development timelines while also helping to reduce program risk.
Specifically, she discusses our high-performing CHO-K1 cell line and process intensification platform, which achieves titers of up to 11 g/L* and is enhanced by AI/ML-driven vector design and clone optimization to improve expression, stability, and speed. She also explores how our single-use bioreactor strategy can help streamline development timelines even further.
What you'll learn in the webinar
Watch the webinar to learn more about:
- Our planned expansion of mAb manufacturing capacity in Plainville, MA
- An advanced CHO-K1 platform powered by AI/ML technology
- How our end-to-end biologics platform speeds up development
- The advantages of integrated process characterization and validation
- Our risk-mitigated development approach with flexible scalability
*Terms and Conditions: Titer levels provided are estimates based on third-party results and may vary depending on molecule type and other factors. Timelines from DNA to drug product and start of clinical trials for all Path to IND for biologics options may vary depending on molecule type and other factors and are estimates to be finalized after third-party cell line development dates are available. The 8-month timeline is based on US-based sites only and may incur additional risk.